Results 281 to 290 of about 80,027 (384)

Is It Safe to Initiate/Optimize the Medication of HFrEF Patients During Hospitalization for Acute Decompensation? [PDF]

J Clin Med
Christodorescu RM, Brie DM, Brie AD, Mornoș C, Drăgan SR, Luca CT, Dărăbanțiu D, Tîrziu A.   +7 more
europepmc   +1 more source

Effects of YM358, an Angiotensin II Type 1(AT1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models.

, 2000
Takamitsu Tokioka, Masayuki Shibasaki, Akira Fujimori, Yasuko Matsuda-Satoh, Wataru Uchida, Osamu Inagaki, I. YANAGISAWA   +6 more
openalex   +2 more sources

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Francisca Saraiva, Ana C. Oliveira, Jorge Almeida, Ana Beatriz Batista, Arsénio Barbosa, Ana Filipa Ferreira, Cátia Costa, Diogo Santos‐Ferreira, Fernando Friões, Cândida Goncalves, João Tiago Guimarães, Marta Leite, Pedro Marques, Joana Mascarenhas, Maria Inês Matos, Catarina Pereira, Pedro Rodrigues, Abhinav Sharma, Gualter Silva, Inês Pereira‐Sousa, Carla Sousa, Faiez Zannad, Joana Pimenta, Ricardo Fontes‐Carvalho, Adelino Leite‐Moreira   +26 more
wiley   +1 more source

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. [PDF]

JACC Adv
Alfarano M, Marchionni G, Costantino J, Ballatore F, Verardo R, Miraldi F, Ciciarello FL, Petramala L, Letizia C, Frustaci A, Chimenti C.   +10 more
europepmc   +1 more source

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair

ESC Heart Failure, EarlyView.
Abstract Aims Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge‐to‐edge mitral valve repair (M‐TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.
Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bouta, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Daisuke Hachinohe, Toshiaki Otsuka, Shunsuke Kubo, Kentaro Hayashida, OCEAN‐Mitral Investigators   +30 more
wiley   +1 more source

Multiregional Implementation Initiative's Impact on Guideline-Based Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF. [PDF]

Circ Heart Fail
Sauer AJ, Beon C, Cherkur S, Mallas-Serdynski L, Thomas K, Spertus J, Chahoud G, Mody KP, Saltzberg MT, Goldberg LR, Lindenfeld J, Sweitzer N, Butler J, Kittleson MM, Pina I, Paul S, Lewis EF, Wald J, Allen LA, Jessup M, Congdon M, Kiser R, Yancy C, Fonarow GC.   +23 more
europepmc   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

ESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang, Rui Fan, Shaozhao Zhang, Junlin Zhong, Yiquan Huang, Peihan Xie, Shanshan Yin, Xiaomin Ye, Xinghao Xu, Rihua Huang, Zhenyu Xiong, Yue Guo, Menghui Liu, Yifen Lin, Suhua Li, Xiaoxian Qian, Jinlai Liu, Xiaodong Zhuang, Xinxue Liao   +18 more
wiley   +1 more source

Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS). [PDF]

Pragmat Obs Res
Richard EL, Desai NR, Willey VJ, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng CC, Oberprieler NG.   +9 more
europepmc   +1 more source

BENEFICIAL EFFECT OF LOSARTAN, ONE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, ON CYCLOSPORINE NEPHROTOXICITY.

, 2000
Akira Ishikawa, Kazuo Suzuki, Kimio Fujita   +2 more
openalex   +1 more source

Do differences among heart failure patients affect their access to treatment?

ESC Heart Failure, EarlyView.
Halit Emre Yalvaç, Bulent Gorenek
wiley   +1 more source